ࡱ;   !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~Root Entry  \pCalc Ba=D  !"=@ 8X@"1Calibri1Arial1Arial1Arial1Calibri1Calibri General3._(\$* #,##0_);_(\$* \(#,##0\);_(\$* \-_);_(@_)!"($"#,##0_);[RED]"($"#,##0\) #,##0\(#,##0_);[RED]\(#,##0\) #,##0.00'""($"#,##0.00_);[RED]"($"#,##0.00\);6_(\$* #,##0.00_);_(\$* \(#,##0.00\);_(\$* \-??_);_(@_)#\(#,##0.00_);[RED]\(#,##0.00\)                + ) , *   ( (8  (  $  $   (       (  $ (8  $   ( `"nresearch and development e"ugeneral and administrative$zgeneral and administrative-1$N~general and administrative-2$pgeneral and administrative-3$"general and administrative-4Tbalance sheets statements of operations"statements of shareholdersstatement of cash flows!net income loss per share 3 investments 4 property and equipment 5 intangible assets~5 intangible assets-16 accrued expenses"7 common stock purchase wawarrant liability"P8 share based compensation# restricted stock units rsus stock optionsstock options-1stock options-2"vcorporate office manufactR11 income taxes11 income taxes-1 11 income taxes-2 advaxis inc". section 302 of the sarbane$section 302 of the sarbane-1$section 302 of the sarbane-2$`section 302 of the sarbane-3"as adopted pursuant to sec$as adopted pursuant to sec-1TbZ #""      !"3  @@   +|!Research and Development ExpensesYears Ended October 31,Increase (Decrease)20182017$%HPV-associated cancers(9)%*Personalized neoantigen-directed therapies4Hotspot mutation-based  off the shelf therapiesProstate cancerOther expensesPartner reimbursements$Total research & development expense(19QStock-based compensation expense included in research and development expense(50#General and Administrative Expenses&General and administrative expense(51SStock-based compensation expense included in general and administrative expense(81Amended and Restated Bylaws. Incorporated by reference to Exhibit 10.4 to Quarterly Report on Form 10-QSB filed with the SEC on September 13, 2006.Form of Common Stock certificate. Incorporated by reference to Exhibit 4.1 to Current Report on Form 8-K filed with the SEC on October 23, 2007.Form of Common stock Purchase Warrant. Incorporated by reference to Exhibit 4.1 to Current Report on Form 8-K filed with the SEC on August 31, 2011.Form of Representative s Warrant. Incorporated by reference to Exhibit 4.19 to Registration Statement on Form S-1/A (File No. 333-188637) filed with the SEC on September 27, 2013.Form of Representative s Warrant related to the Underwriting Agreement, dated as of March 31, 2014, by and between Advaxis, Inc. and Aegis Capital Group. Incorporated by reference to Exhibit 4.2 to Quarterly Report on Form 10-Q filed with the SEC on June 10, 2014.-Form of Warrant Agency Agreement, dated as of September 11, 2018 between Advaxis, Inc. and Continental Stock Transfer and Trust Company (and Form of Warrant contained therein), Incorporated by reference to Exhibit 4.1 to Current Report on Form 8-K filed with the SEC on September 11, 2018.SForm of Common Stock Warrant dated September 11, 2018 (included in Exhibit 4.5)2004 Stock Option Plan of the registrant. Incorporated by reference to Exhibit 4.1 to Report on Form S-8 filed with the SEC on December 1, 2005.2005 Stock Option Plan of the registrant. Incorporated by reference to Annex A to DEF 14A Proxy Statement filed with the SEC on May 15, 2006.%License Agreement, between the Trustees of the University of Pennsylvania and the registrant dated as of June 17, 2002, as Amended and Restated on February 13, 2007. Incorporated by reference to Exhibit 10.11 to Annual Report on Form 10-KSB filed with the SEC on February 13, 2007.Amended and Restated 2009 Stock Option Plan of the registrant. Incorporated by reference to Annex A to DEF 14A Proxy Statement filed with the SEC on April 30, 2010.$Second Amendment to the Amended and Restated Patent License Agreement between the registrant and the Trustees of the University of Pennsylvania dated as of May 10, 2010. Incorporated by reference to Exhibit 10.1 to Quarterly Report on Form 10-Q filed with the SEC on June 3, 2010.2011 Omnibus Incentive Plan of registrant. Incorporated by reference to Annex A to DEF 14A Proxy Statement filed with the SEC on August 29, 2011.Amendment No. 1 to the Advaxis, Inc. 2011 Employee Stock Purchase Plan. Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on December 20, 2011.TAmendment No. 1, dated as of March 26, 2007, to the License Agreement, between the Trustees of the University of Pennsylvania and Advaxis, Inc. dated as of June 17, 2002, as amended and restated on February 13, 2007. Incorporated by reference to Exhibit 10.1 to Quarterly Report on Form 10-Q filed with the SEC on June 14, 2012.WAmendment No. 3, dated as of December 12, 2011, to the License Agreement, between the Trustees of the University of Pennsylvania and Advaxis, Inc. dated as of June 17, 2002, as amended and restated on February 13, 2007. Incorporated by reference to Exhibit 10.5 to Quarterly Report on Form 10-Q filed with the SEC on June 14, 2012.Amendment No. 1 to 2011 Omnibus Incentive Plan of registrant. Incorporated by reference to Annex B to DEF 14A Proxy Statement filed with the SEC on July 19, 2012.Indemnification Agreement. Incorporated by reference to Exhibit 10.3 to Current Report on Form 8-K filed with the SEC on August 20, 2013. 10.12 ! Employment Agreement between Advaxis, Inc. and Robert Petit, dated September 26, 2013. Incorporated by reference to Exhibit 10.70 to Registration Statement on Form S-1/A (File No. 333-188637) filed with the SEC on September 27, 2013.Exclusive License and Technology Transfer Agreement by and between Advaxis, Inc. and Global BioPharma, Inc., dated December 9, 2013. Incorporated by reference to Exhibit 10.79 to Annual Report on Form 10-K/A filed with the SEC on February 6, 2014.10.14! Amendment No. 1, dated as of December 19, 2013, to the Employment Agreement by and between Advaxis, Inc. and Robert G. Petit. Incorporated by reference to Exhibit 10.82 to Annual Report on Form 10-K/A filed with the SEC on February 6, 2014.Distribution and Supply Agreement, dated as of January 20, 2014, by and between Advaxis, Inc. and Biocon, Limited. Incorporated by reference to Exhibit 10.7 to Quarterly Report on Form 10-Q filed with the SEC on March 17, 2014.Exclusive License Agreement, dated March 19, 2014, by and between Advaxis, Inc. and Aratana Therapeutics, Inc. Incorporated by reference to Exhibit 10.1 to Quarterly Report on Form 10-Q filed with the SEC on June 10, 2014.10.17! Amendment No. 2, dated as of June 5, 2014, to the Employment Agreement by and between Advaxis, Inc. and Robert G. Petit. Incorporated by reference to Exhibit 10.6 to Quarterly Report on Form 10-Q filed with the SEC on June 10, 2014.Clinical Trial Collaboration Agreement, dated July 21, 2014, by and between Advaxis, Inc. and MedImmune, LLC. Incorporated by reference to Exhibit 10.1 to Quarterly Report on Form 10-Q filed with the SEC on September 9, 2014. 5th Amendment to the Amended & Restated License Agreement, dated July 25, 2014, by and between Advaxis, Inc. and University of Pennsylvania. Incorporated by reference to Exhibit 10.2 to Quarterly Report on Form 10-Q filed with the SEC on September 9, 2014.Amendment No. 2 to the Advaxis, Inc. 2011 Omnibus Incentive Plan, effective July 9, 2014. Incorporated by reference to Annex A to Current Report on Schedule 14A filed with the SEC on May 20, 2014.Amended and Restated 2011 Omnibus Incentive Plan, dated September 8, 2014. Incorporated by reference to Exhibit 10.4 to Quarterly Report on Form 10-Q filed with the SEC on September 9, 2014.Master Services Agreement for Technical Transfer and Clinical Supply, dated February 5, 2014, by and between Advaxis, Inc. and SynCo Bio Partners B.V. Incorporated by reference to Exhibit 10.1 to Current Report to Form 8-K filed with the SEC on February 11, 2014.Clinical Trial Collaboration and Supply Agreement by and between Advaxis, Inc. and Merck & Co. dated August 22, 2014. Incorporated by reference to Exhibit 10.101 to Annual Report on Form 10-K filed with the SEC on January 6, 201510.24! Amendment No. 3, dated as of April 17, 2015, to the Employment Agreement by and between Advaxis, Inc. and Robert G. Petit. Incorporated by reference to Exhibit 10.6 to Quarterly Report on Form 10-Q filed with the SEC on June 15, 2015.Exclusive License Agreement, dated August 25, 2015, by and between Advaxis, Inc. and Knight Ther< apeutics, Inc. Incorporated by reference to Exhibit 10.57 to Annual Report on Form 10-K filed with the SEC on January 8, 2016.10.26! Amendment No. 4, dated as of December 31, 2015, to the Employment Agreement by and between Advaxis, Inc. and Robert G. Petit. Incorporated by reference to Exhibit 10.58 to Annual Report on Form 10-K filed with the SEC on January 8, 2016.Co-Development and Commercialization Agreement between Advaxis, Inc. and Especificos Stendhal SA de CV dated February 3, 2016. Incorporated by reference to Exhibit 10.1 to Quarterly Report on Form 10-Q filed with the SEC on February 26, 2016.10.28! Separation Agreement and General Release, dated July 6, 2017, between Advaxis, Inc. and Daniel J. O Connor. Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on July 7, 2017.2015 Incentive Plan of registrant. Incorporated by reference to Annex A to DEF 14A Proxy Statement filed with the SEC on April 7, 2015.10.30! TSeparation Agreement and General Release, dated April 23, 2018, between Advaxis, Inc. and Anthony Lombardo. Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on April 23, 2018.10.31! 9Employment Agreement between Advaxis, Inc. and Molly Henderson, dated June 6,2018. Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on June 6, 2018.Code of Business Conduct and Ethics dated July 9, 2014. Incorporated by reference to Exhibit 14.1 to Current Report on Form 8-K filed with the SEC on July 10, 2014.=Consent of Independent Registered Public Accounting Firm.31.1*fCertification of Chief Executive Officer pursuant to section 302 of the Sarbanes-Oxley Act of 200231.2*fCertification of Chief Financial Officer pursuant to section 302 of the Sarbanes-Oxley Act of 200232.1*fCertification of Chief Executive Officer pursuant to section 906 of the Sarbanes-Oxley Act of 200232.2*fCertification of Chief Financial Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002 101.INS**XBRL Instance Document 101.SCH**+XBRL Taxonomy Extension Schema Document 101.CAL**9XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF**9XBRL Taxonomy Extension Definitions Linkbase Document 101.LAB**3XBRL Taxonomy Extension Label Linkbase Document 101.PRE**:XBRL Taxonomy Extension Presentation Linkbase DocumentBALANCE SHEETSOctober 31,ASSETSCurrent assets:Cash and cash equivalentsRestricted cash$Short-term investment securities-Income tax receivableDeferred expenses-Prepaid expenses and other current assetsTotal current assets<Property and equipment (net of accumulated depreciation)7Intangible assets (net of accumulated amortization) Other assets Total assets(LIABILITIES AND SHAREHOLDERS EQUITYCurrent liabilities:Accounts payableAccrued expensesDeferred revenue"Common stock warrant liabilityOther current liabilitiesTotal current liabilitiesOther liabilitiesTotal liabilities+Commitments and contingencies  Note 10Shareholders equity:Preferred stock, $0.001 par value; 5,000,000 shares authorized; Series B Preferred Stock; 0 shares issued and outstanding at October 31, 2018 and 2017. Liquidation preference of $0 at October 31, 2018 and 2017.Common stock - $0.001 par value; 95,000,000 shares authorized, 69,556,452 shares issued and outstanding at October 31, 2018 and 41,206,538 shares issued and outstanding at October 31, 2017.Additional paid-in capitalAccumulated deficitTotal shareholders equity.Total liabilities and shareholders equitySTATEMENTS OF OPERATIONSYear Ended October 31,RevenueOperating expenses:%Research and development expenses'General and administrative expensesTotal operating expensesLoss from operationsOther income (expense):Interest income7Net changes in fair value of derivative liabilitiesOther expense&Net loss before income tax benefit Income tax expense (benefit)Net loss0Net loss per common share, basic and dilutedKWeighted average number of common shares outstanding, basic and diluted"STATEMENTS OF SHAREHOLDERS EQUITYPreferred StockCommon StockAdditional Paid-InTreasury Stock AccumulatedTotal Shareholders SharesAmountCapitalDeficitEquityBalance at October 31, 2016$-Stock based compensationJTax withholdings paid related to net share settlement of equity awards*Tax withholdings paid on equity awards@Tax shares sold to pay for tax withholdings on equity awards1Common stock issued upon exercise of warrants3Issuance of shares to employees under ESPP PlanAdvaxis at-the-market sales Net LossBalance at October 31, 2017Advaxis public offeringsBalance at October 31, 2018STATEMENT OF CASH FLOWSOPERATING ACTIVITIESOAdjustments to reconcile net loss to net cash used in operating activities:Stock compensation(Employee stock purchase plan expense'Gain on change in value of warrants.Loss on disposal of property and equipment"Write-off of intangible assetsDepreciation expense-Amortization expense of intangible assets:Net (accretion) amortization of premiums and discounts/Change in operating assets and liabilities:-Prepaid expenses and other current assetsIncome taxes receivable)Accounts payable and accrued expenses)Net cash used in operating activitiesINVESTING ACTIVITIES?Restricted cash established with letter of credit agreementPurchases of investments@Proceeds from maturities of short-term investment securities"Purchase of property and equipmentCost of intangible assets7Net cash provided by (used in) investing activitiesFINANCING ACTIVITIES9Net proceeds of issuance of common stock and warrants&Proceeds from the exercise of warrants.Proceeds from employee stock purchase planJTax withholdings paid related to net share settlement of equity awards3Employee tax withholdings paid on equity awardsITax shares sold to pay for employee tax withholdings on equity awards-Net cash provided by financing activities8Net increase (decrease) in cash and cash equivalents2Cash and cash equivalents at beginning of year,Cash and cash equivalents at end of yearNet Income (Loss) per ShareAs of October 31,Warrants Stock optionsRestricted stock unitsTotal3. INVESTMENTSOctober 31, 2017!Amortized Cost, as Adjusted$Gross Unrealized Holding Gains%Gross Unrealized Holding LossesEstimated Fair ValueShort-term investments:Certificates of Deposit"Domestic Governmental Agency LoansU.S Treasury Notes*Total short-term investment securities4. PROPERTY AND EQUIPMENTLeasehold improvementsLaboratory equipmentFurniture and fixturesComputer equipmentConstruction in progressTotal property and equipment-Accumulated depreciation and amortizationNet property and equipment5. INTANGIBLE ASSETSPatentsLicenseSoftwareTotal intangiblesAccumulated< amortizationNet intangible assets20192020202120222023 Thereafter6. ACCRUED EXPENSES:Salaries and other compensationVendorsProfessional feesTotal accrued expenses77. COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY%Weighted Average Exercise Price<Weighted Average Remaining Contractual Life In YearsAggregate Intrinsic Value<Outstanding and exercisable warrants at October 31, 2016 ExercisedExpired<Outstanding and exercisable warrants at October 31, 2017Issued<Outstanding and exercisable warrants at October 31, 2018Warrant LiabilityOctober 31 ,2018Exercise Price Stock Price Expected Term35.87 years Volatility %97.47%Risk Free Rate3.03%8. SHARE BASED COMPENSATIONResearch and developmentGeneral and administrativeRestricted Stock Units (RSUs)Number of RSU s+Weighted-Average Grant Date Fair Value Balance at October 31, 2016:GrantedVested CancelledBalance at October 31, 2018 Stock Options&Outstanding as of October 31, 2016Cancelled or expired&Outstanding as of October 31, 2017&Outstanding as of October 31, 2018.Vested and exercisable at October 31, 2018Options OutstandingOptions ExercisableWeightedAverageExerciseNumber Remaining IntrinsicPrice Range Outstanding ContractualPriceValue Exercisable$0.60 - $4.99$5.00 - $9.99$10.00 - $14.99$15.00 - $21.25Year EndedOctober 31, 20182Weighted average fair value of options grantedExpected term85.35-6.51 years85.50-6.50 yearsExpected volatility91.14%-100.34%107.07%-110.93%Expected dividends0%Risk free interest rate 1.81%-3.16% 1.26%-1.58%/Corporate Office & Manufacturing Facility LeaseYear ended October 31,11. INCOME TAXES:FederalCurrentDeferredState and Local!Change in valuation allowance"Income tax provision (benefit)Years EndedDeferred Tax Assets!Net operating loss carryoversStock-based compensation$Research and development creditsDeferred revenueOther deferred tax assetsTotal deferred tax assetsValuation allowance2Deferred tax asset, net of valuation allowanceDeferred Tax Liabilities"Other deferred tax liabilities"Total deferred tax liabilities&Net deferred tax asset (liability)US Federal statutory rate23.17%34.00%,State income tax, net of federal benefitPermanent differences=Income tax benefit from sale of New Jersey NOL carryoversTax Cuts and Jobs ActOther"Income tax (provision) benefit0.00%4.55% Advaxis INC/s/ Marcum llpMarcum llpNew York, NYJanuary 11, 2019/(SECTION 302 OF THE SARBANES OXLEY ACT OF 2002)iI have reviewed this annual report on Form 10-K for the year ended October 31, 2018 of Advaxis, Inc.;6Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;#Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;PThe registrant s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:(a)zDesigned such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;(b)sDesigned such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;(c)Evaluated the effectiveness of the registrant s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and(d)Disclosed in this report any change in the registrant s internal control over financial reporting that occurred during the registrant s most recent fiscal quarter (the registrant s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant s internal control over financial reporting; and+The registrant s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant s auditors and the audit committee of the registrant s board of directors (or persons performing the equivalent functions):All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant s ability to record, process, summarize and report financial information; andAny fraud, whether or not material, that involves management or other employees who have a significant role in the registrant s internal control over financial reporting.By:/s/ Kenneth BerlinName:Kenneth Berlin<Title:'President & Chief Executive Officer/s/ Molly HendersonMolly Henderson5Chief Financial Officer, Executive Vice PresidentDAS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002Date: January 11, 2019 Gcc   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} Q} }  } }  }  } } }  } } , @ ,,,,, , , , ,,                 ~ B{~ j~       ~ n$~ #~  ~   ~ ~ ~  ~   ~ r,~ <~ ~   ~ J~ ~ .~ ~  ~ ~ [~ J~ N ~ *z ~ M ~ z,    ~ R,~ BX~            PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} S} } } }  , @ ,,,,                 ~ B0~ p~      ~ @~ Z~          PH 0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} }  } } d} ,,,, , , ,,,,~  ffffff@ ~  ~   @ ~    ffffff@ ~  ffffff$@ ~   PH0 0(   >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} }  } } d} ,,,, , , ,~ C !~ k "~  #~  $~  %~   &~  'PH@0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} }  } } d} ,,,, , , ,,,,,,,,,~  ( ) *(\B$@ + , -~  .~  / 0 1~  2~  3ffffff$@ 4Qk$@ 5q= ףp$@ 6~  7 8 9~  :PHP0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} }  } } d} $,,,, , , ,,,,,,,,,, ; <~  = > ?~  @ A B C D~   E~ $ F G H I J K L M N O P Q R S T U V!,#, !W !X #Y #ZPH`0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} d} }  } }  } +,,@,,,,, , , , , ,,,,,,,,,,,,,,, [ \   ]   ^ _~ ~ ru `~ F~ . a b~  c b~ E d~ b ~ . e~ .3~ - f~ ~ n g~ rh~ o h~ K~ K i~ b~  j~ ~ * k l m~ :X~ P n~ `~  o~ E~ Nm p~ e b q~ ~  r~ be~ F o~ ~  s~ ~ > ,",$,%,&,',(,),*, t~ "U~ Zg "u $v %w %b %b &x~ &~ & 'y~ 'Z~ ' (z~ (^~ ( ){~ )w~ )O *|~ **~ ***r****PHp0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} K} }  } }  } ,,@,,,, , , , ,,,,,,,,,, } ~     ~ ^~   ~ *z~ M ~ B0~ p ~ j~ 6 ~ V~   ~  ~ z ~ "5~ R ~ ~  ~ ~~ J ~ ~ 6 ~ ~ L ~   ~  g ~ H ~  b PH 0(   >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} J} } }  } } }  } }  } }  } }  } }  } "} ## } $$,$ @$,$,$,$,$, $, $, $, $, $,$,$,$,$,$,$,$,$,$,$,         "!#!           "#  b ~   ~ ~ ~ ~ ~ R~ "H# ~  >~ ~ f~ #j ~ n~ #n ~ n~ n&~ >~ # ~ . ~ ~ ~ # ~ ~ ~ # ~ ~ ~ # ~ Ɵ~ B ~ #B ~ L~ #L  b ~  * ~ ~  b ~ ~ "O# ~  B.~ ~ m~ #m ~ ~ # ~ ~ # ~ 2~ #2 ~  d~ ~ # ~  v5~ ~ )~ #) ~  [~ n~ N~ # ~ ~ #  b ~  c~ ~ Z b ~ ^~ "w#" "# "#"#"#"#PH$0(  $>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} O} }  } }  } ,,,@,,,,, , , , , ,,,,,,,,,,,,,,,,,,  ~    ~ ~ L  ~ m~  ~ ~ B ~ ~  ~  ~  ~ ^~  ~ f~ ^ ~ ~ * ~ ~   ~  ~ 2 ~ E~ F i~ ^~  ~ z~ " o~ >~ G s~ ~  ~ >5~ ZO  ~ ~  ~ <~ ާ ~ .~  ~ ~  ~ ~  ~ ~ b=!,",#,$,%,&,',(,),*,+, ! "~ ":e~ "B # #b~ # $~ $~ $ %~ %~ %n &~ &~ & '~ '2~ ' (~ (vd~ ( )~ )F<~ ) *~ *ru~ * +~ ++~ +ru+B++++PH(0(  (>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  }  ,,@,,,,,     ~ `~ Ǽ ~ &0.~ ڤ ~ ~ 2S ~ ~ "PH,0(  ,>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} *} }  } } }  } } }  }  ,,@ @,,,, ,           ~     ~  ~  b  b~  ~ . b~  f~  ~    ~ f ~  r     PH00(  0>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} -} }  } }  }  ,,@,,,,, , , , ,  \   ~ F$~ ! ~ V~ vD ~  ~ f ~ f~ . ~ F~  ~ ~  ~ ~ & ~ rh ~ o B  PH40(  4>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  }  ,,@,,,,, , ,  \   ~ J]~ ~Y ~ & ~ & ~ ~  ~ Bk~ Vg ~ Z~  ~ K ~ K B  PH80(  8>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } ,,,,,,, ~ " ~  ~  ~  ~  ~ . ~ KPH<0(  <>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  }  ,,@,,,,,  \   ~ ~ v) ~ 29~ + ~ ~ 2 ~ `~ BPH@0(  @>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} <} }  } }  }  } }  , @,,,,, , ,        ~ ڽ~ ""~  ~ Z ~ ~~  ~ v~  ~ ~ ""~  s  ~ *`~ [ ~ FnC~  ~ `~ "[ "~ /  Z    PHD0(  D>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } 3}  ,,@,,,,,   ~ "[" "Q?"      "PH H0(  H>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  } ,,@,,,,   ~    ~ R,~ BX  ~ @~ Z ~ m~ BPH0L0(  L>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  } }  }  , @,,,,, , , , ,      ~ b+~ "" ~ c~ [ ~ r~ O ~ b8~  ~ 2S"Gz!@" ~ z~  ~ ~~  ~ *~  ~  "(\@ "2 PH@P0(  P>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} .} }  } }  }  } }  , @,,,,, , , ,        ~ Γ~ ""~  ; ~  ~ b!~  ~ ~  ~ ڤ~ ""~    ~ ~ ; ~ ڦ~ K ~ &0.~ "  "~ C   ~ ~ "  "~   j      PHPT0(  T>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} }  } }  } }  } }  }  !!,@!,!,!,!,@!,@!,@!,@ !,@                                   !     !  " # $  %  & ' $ % &  (~ U|(\#@~  " " ~ * ~ _ ~ " "   )~ 6 ~ #~  "{  " ~ B~ ~ " "   *~ @~ ~  " " ~ ~Gz@~ ""   + ~ ~ ~ ~ "S "  ~ ~ ~ ~ "S "  <                    PH`X0(  X>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} 2} } 8} } 8} ,@,@,,,,, , -  .~ ""~ " " / 0 1 2 3 4 5 6 6 7 8 9*PHp\0(  \>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } }  }  ,,,,,,, , , , : ;   ~ N ~ F ~  ~ f ~  ~ . ~  * PH`0(  `>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} "} }  } }  }  ,,@,,,,, , , , < -  = >   ?~ \~ " @ > b~ n ?~ ު~ r A~ R~ r) B  ~ n :  PHd0(  d>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} 2} }  } }  } ,@,@,,,,,, , , , ,,,, C -  D E~ ~  F~ Ƽ~ V G~ j~ q H~ Q~  I~ . ~  J~ z ~ Ɗ  K~ *~ z L~  ~ >&  M N~ Z~  O~ Z~  P  z    PHh0(  h>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} =} }  } }  }  ,@,@,,,,,, , , , C -  Q R S T~  ffffff? U~ #ffffff G~ #k~  V b~  A~ '#B W~ # b X~ #S~  Y Z [PHl0(  l>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } ,,,,, \ $] ^ _ ` PHp0(  p>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } d} ,,@,@,@ ,@ , , ,,,,@,,, a~  b~  c~  d~  e   f g h i j k l m~  n  f o h pB  PHt0(  t>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } '} ,@,,,, `   q $r s t u vPHx0(  x>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } d} ,,@,@,@ ,@ , , ,,,,@,,, a~  b~  c~  d~  e   f g h i j k l m~  n  f o h pB  PH|0(  |>@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } 5} ,@,,,, `  q $w s x u yPH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } '} ,,,, z { q $r s t u v PH0(  >@<dgg   d-C6?_%,*+&ffffff?'ffffff?(?)?"d,, ` `? ` `?U} } } 5} ,,,, z { q $w s x u y PH 0(  >@<dgg   FMicrosoft Excel 97-TabelleBiff8Oh+'0|8 @ L X d p0@@@Pӊ@Pӊ՜.+,D՜.+,\ H AppVersion DocSecurityHyperlinksChangedLinksUpToDate ScaleCrop ShareDoc12.0000 Root EntryFWorkbookNCompObjIOle SummaryInformation(DocumentSummaryInformation8h